Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment

Chih Hsin Yang, Min Chun Chen, Ann Lii Cheng, Chih Hung Hsu, Kun Huei Yeh, Yu Chie Yu, Jacqueline Whang-Peng, Pan Chyr Yang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. Methods: Eligibility criteria included inoperable stage IIIB or IV NSCLC patients, Eastern Cooperative Oncology Group performance status of 0-2, measurable or evaluable disease and adequate organ function. Epirubicin 70 mg/m2 intravenous infusion for 15 min was given on day 1. Paclitaxel 175 mg/m 2 intravenous infusion for 3 h was given on day 2. Cycles were repeated every 21 days. Tumor response was evaluated every two cycles. Patients received treatment until disease progression, unacceptable toxicity or stable disease after cycle 6. Results: Thirty-eight patients received a total of 185 cycles (median 6 cycles). Seventeen patients responded to treatment (response rate 44.7%). Twenty-six (68%) patients received second-line chemotherapy. All patients were followed until their death. Median survival was 11.9 months (95% confidence interval 9.0-14.9 months). Median time-to-treatment-failure was 4.6 months. Conclusion: Conventional dose epirubicin plus paclitaxel is effective as a first-line treatment for inoperable NSCLC patients.

Original languageEnglish
Pages (from-to)350-355
Number of pages6
JournalOncology
Volume68
Issue number4-6
DOIs
Publication statusPublished - Aug 1 2005
Externally publishedYes

Fingerprint

Epirubicin
Paclitaxel
Non-Small Cell Lung Carcinoma
Survival
Therapeutics
Intravenous Infusions
Anthracyclines
Treatment Failure
Disease Progression
Neoplasms
Confidence Intervals
Drug Therapy

Keywords

  • Chemotherapy
  • Epirubicin
  • Non-small cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment. / Yang, Chih Hsin; Chen, Min Chun; Cheng, Ann Lii; Hsu, Chih Hung; Yeh, Kun Huei; Yu, Yu Chie; Whang-Peng, Jacqueline; Yang, Pan Chyr.

In: Oncology, Vol. 68, No. 4-6, 01.08.2005, p. 350-355.

Research output: Contribution to journalArticle

Yang, Chih Hsin ; Chen, Min Chun ; Cheng, Ann Lii ; Hsu, Chih Hung ; Yeh, Kun Huei ; Yu, Yu Chie ; Whang-Peng, Jacqueline ; Yang, Pan Chyr. / Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment. In: Oncology. 2005 ; Vol. 68, No. 4-6. pp. 350-355.
@article{1ae5a229a3c349e69974d15e8ca1fe14,
title = "Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment",
abstract = "Objective: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. Methods: Eligibility criteria included inoperable stage IIIB or IV NSCLC patients, Eastern Cooperative Oncology Group performance status of 0-2, measurable or evaluable disease and adequate organ function. Epirubicin 70 mg/m2 intravenous infusion for 15 min was given on day 1. Paclitaxel 175 mg/m 2 intravenous infusion for 3 h was given on day 2. Cycles were repeated every 21 days. Tumor response was evaluated every two cycles. Patients received treatment until disease progression, unacceptable toxicity or stable disease after cycle 6. Results: Thirty-eight patients received a total of 185 cycles (median 6 cycles). Seventeen patients responded to treatment (response rate 44.7{\%}). Twenty-six (68{\%}) patients received second-line chemotherapy. All patients were followed until their death. Median survival was 11.9 months (95{\%} confidence interval 9.0-14.9 months). Median time-to-treatment-failure was 4.6 months. Conclusion: Conventional dose epirubicin plus paclitaxel is effective as a first-line treatment for inoperable NSCLC patients.",
keywords = "Chemotherapy, Epirubicin, Non-small cell lung cancer, Paclitaxel",
author = "Yang, {Chih Hsin} and Chen, {Min Chun} and Cheng, {Ann Lii} and Hsu, {Chih Hung} and Yeh, {Kun Huei} and Yu, {Yu Chie} and Jacqueline Whang-Peng and Yang, {Pan Chyr}",
year = "2005",
month = "8",
day = "1",
doi = "10.1159/000086974",
language = "English",
volume = "68",
pages = "350--355",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4-6",

}

TY - JOUR

T1 - Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment

AU - Yang, Chih Hsin

AU - Chen, Min Chun

AU - Cheng, Ann Lii

AU - Hsu, Chih Hung

AU - Yeh, Kun Huei

AU - Yu, Yu Chie

AU - Whang-Peng, Jacqueline

AU - Yang, Pan Chyr

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Objective: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. Methods: Eligibility criteria included inoperable stage IIIB or IV NSCLC patients, Eastern Cooperative Oncology Group performance status of 0-2, measurable or evaluable disease and adequate organ function. Epirubicin 70 mg/m2 intravenous infusion for 15 min was given on day 1. Paclitaxel 175 mg/m 2 intravenous infusion for 3 h was given on day 2. Cycles were repeated every 21 days. Tumor response was evaluated every two cycles. Patients received treatment until disease progression, unacceptable toxicity or stable disease after cycle 6. Results: Thirty-eight patients received a total of 185 cycles (median 6 cycles). Seventeen patients responded to treatment (response rate 44.7%). Twenty-six (68%) patients received second-line chemotherapy. All patients were followed until their death. Median survival was 11.9 months (95% confidence interval 9.0-14.9 months). Median time-to-treatment-failure was 4.6 months. Conclusion: Conventional dose epirubicin plus paclitaxel is effective as a first-line treatment for inoperable NSCLC patients.

AB - Objective: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. Methods: Eligibility criteria included inoperable stage IIIB or IV NSCLC patients, Eastern Cooperative Oncology Group performance status of 0-2, measurable or evaluable disease and adequate organ function. Epirubicin 70 mg/m2 intravenous infusion for 15 min was given on day 1. Paclitaxel 175 mg/m 2 intravenous infusion for 3 h was given on day 2. Cycles were repeated every 21 days. Tumor response was evaluated every two cycles. Patients received treatment until disease progression, unacceptable toxicity or stable disease after cycle 6. Results: Thirty-eight patients received a total of 185 cycles (median 6 cycles). Seventeen patients responded to treatment (response rate 44.7%). Twenty-six (68%) patients received second-line chemotherapy. All patients were followed until their death. Median survival was 11.9 months (95% confidence interval 9.0-14.9 months). Median time-to-treatment-failure was 4.6 months. Conclusion: Conventional dose epirubicin plus paclitaxel is effective as a first-line treatment for inoperable NSCLC patients.

KW - Chemotherapy

KW - Epirubicin

KW - Non-small cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=23844505957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844505957&partnerID=8YFLogxK

U2 - 10.1159/000086974

DO - 10.1159/000086974

M3 - Article

C2 - 16020962

AN - SCOPUS:23844505957

VL - 68

SP - 350

EP - 355

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4-6

ER -